A pilot phase IIa study (NCT00948259) has reported promising effects of tideglusib, a novel inhibitor of glycogen synthase-3 (GSK-3), in 30 patients with mild to moderate Alzheimer’s disease (Del Ser et al. J Alzheimers Dis 2013;33:205-215).
It takes 30 seconds or login using your email address
Please enter the email address that you registered the newsletter with